Diethylcarbamazine has antiparasitic activity primarily against microfilariae. It alters the interaction of the parasites with the host immune system and facilitates their elimination from tissues and the bloodstream.
The medicine may be used:
Diethylcarbamazine has been studied for several decades and remains an established treatment for certain filarial infections. Clinical studies and mass-treatment programs in endemic areas have demonstrated its ability to substantially reduce circulating microfilariae and support the treatment and control of lymphatic filariasis. Treatment effectiveness depends on the parasite species, disease stage, and therapeutic regimen.
Diethylcarbamazine should not be considered a universal treatment for all intestinal or tissue worms. Different parasitic infections may require different medicines. Identification of the causative organism is therefore important before treatment.
The medicine is used for the treatment of selected parasitic diseases, particularly infections caused by filarial worms.
Main indications include:
Diethylcarbamazine acts primarily against microfilariae by interfering with their physiological processes and increasing their susceptibility to elimination by the host immune system. In some filarial infections, treatment may produce inflammatory reactions resulting from parasite death.
The dosage and duration of treatment should be determined by a healthcare professional according to the type of parasitic infection, body weight, age, and clinical condition. Tablets are generally taken orally after meals with sufficient water. Treatment of filarial infections may involve several doses over a defined period. The dosage or treatment duration should not be changed without medical advice.
